Report Highlights

Crop oil concentrates at a turning point: Market Overview

The global crop oil concentrates market was valued at USD 1.84 billion in 2024 and is forecast to reach USD 3.12 billion by 2034, expanding at a CAGR of 5.4%. This market encompasses petroleum-based and vegetable-oil-based adjuvant formulations used to amplify the performance of herbicides, insecticides, and fungicides across field crops, horticulture, and turf applications. North America dominates current revenue, driven by the scale of corn, soybean, and cotton production in the United States, while Asia-Pacific is accelerating sharply as rice and wheat intensification programs expand herbicide use in India, China, and Vietnam.

The current turning point in this market is regulatory and formulation-driven simultaneously. The U.S. Environmental Protection Agency's 2024 draft guidance on inert ingredients and adjuvant labelling is moving toward mandatory disclosure of petroleum distillate content, directly threatening conventional COC formulations that rely on undisclosed hydrocarbon fractions. This regulatory pressure is coinciding with a reformulation cycle in the agrochemical industry as major herbicide manufacturers—including BASF and Corteva—increasingly specify compatible adjuvant classes on new product labels, creating structured demand for technically validated COC products and disadvantaging commodity formulations.

Key forces shaping crop oil concentrate growth

Three forces are driving revenue growth in this market with clear mechanistic links to revenue expansion. First, rising herbicide resistance globally is compelling growers to increase application rates and frequency, which in turn raises adjuvant volumes consumed per acre. In the U.S. alone, Palmer amaranth resistance to glyphosate has pushed growers toward dicamba and 2,4-D tank mixes, both of which show measurably improved efficacy—15 to 22% greater weed control—when paired with validated COC adjuvants. This efficacy link is now embedded in agronomist recommendations, creating a demand pull that is independent of commodity price cycles.

Second, the global expansion of no-till and conservation agriculture practices is increasing post-emergent herbicide dependence, as mechanical weed control is removed from the rotation. Post-emergent herbicides consistently require adjuvant support at higher rates than pre-emergent alternatives, directly expanding COC consumption per cropped hectare. Third, the rapid adoption of precision application technology—variable-rate sprayers and drone-based delivery—is creating demand for optimised adjuvant formulations engineered for low-volume, high-concentration applications. This segment commands a premium over commodity COC formulations and is growing at above-market rates in Europe and Australia, benefiting technically differentiated suppliers disproportionately.

Barriers and risks in the crop oil concentrates market

The most significant structural risk to this market is raw material sourcing vulnerability. Conventional crop oil concentrates rely on petroleum distillate fractions—specifically paraffinic and naphthenic oils—whose availability and pricing are tied to crude oil refining economics and refinery configuration decisions by major petroleum companies. As refineries globally optimise for transportation fuel and petrochemical feedstocks, the supply of specialty agricultural-grade oil fractions is becoming less predictable. This is not a cyclical disruption; it reflects a permanent shift in refinery investment priorities driven by energy transition policies, making petroleum-based COC manufacturers structurally exposed to both supply constraints and rising input costs through the decade.

The more immediate cyclical risk is farmer income sensitivity. Adjuvants are among the first inputs farmers cut during low commodity price periods, as they are perceived as performance enhancers rather than essential inputs—a perception that is commercially inaccurate but persistent. The 2023 pullback in corn and soybean prices caused a documented 6 to 9% volume decline in adjuvant purchases across the U.S. Corn Belt, demonstrating that demand elasticity remains meaningful. Regulatory complexity compounds both risks: state-level restrictions on petroleum-based adjuvants in California and the EU's Farm to Fork adjuvant review process are structural barriers that the bear case for this market cannot ignore.

Emerging opportunities in crop oil concentrates

The clearest near-term opportunity lies in biobased and methylated vegetable oil (MVO) COC formulations. As EPA labelling reform and EU adjuvant regulations increasingly require disclosure and restrict petroleum distillate content, formulators with validated biobased alternatives are positioned to capture shelf space from petroleum-based incumbents. Brandt Consolidated has already commercialised a soy-methyl-ester adjuvant line targeting this transition, and the segment is growing at an estimated 11% annually. The condition for this opportunity to fully materialise is final EPA rulemaking on inert ingredient disclosure, which analysts expect before the end of 2026.

A second opportunity exists in the integration of crop oil concentrates with biological pesticide delivery. As biopesticide adoption accelerates—with the global biopesticide market projected to exceed USD 18 billion by 2030—formulators who develop COC products specifically optimised for biological active ingredients will access an entirely new customer base. Conventional COC chemistries are often incompatible with biological organisms, creating a white space for custom adjuvant platforms. Companies that secure co-label endorsements from leading biopesticide manufacturers such as Marrone Bio Innovations or Certis Biologicals before 2028 will establish defensible distribution advantages that are difficult for generic adjuvant producers to replicate.

Investment case: Bull, bear, and what decides it

The bull case for crop oil concentrates rests on three converging catalysts: accelerating herbicide resistance driving higher adjuvant attachment rates, regulatory frameworks that disadvantage commodity petroleum formulations and reward technically differentiated biobased products, and the structural growth of no-till agriculture globally expanding post-emergent herbicide use per hectare. Under this scenario, the market reaches USD 3.12 billion by 2034, with biobased and specialty adjuvant segments capturing a disproportionate share of margin expansion. Companies with validated formulation platforms, strong agronomist channel relationships, and secured biobased feedstock contracts—such as Wilbur-Ellis and Brandt Consolidated—outperform the market by 200 to 350 basis points annually.

The bear case centres on private-label commoditisation compressing margins across the value chain faster than volume growth can compensate. If farm income remains depressed through 2026 due to sustained soft commodity prices, adjuvant SKU rationalisation by major retailers and co-ops will accelerate, favouring lowest-cost generic formulations over branded COC products. Simultaneously, if EPA rulemaking on adjuvant inerts is delayed beyond 2027, the regulatory catalyst that underpins the biobased transition stalls, removing the primary margin expansion mechanism from the bull thesis. In this scenario, the market grows modestly in volume but real revenue growth is suppressed to 3 to 3.5% annually through 2029.

The swing variable is the pace and specificity of EPA adjuvant inert ingredient regulation. This single regulatory decision determines whether the biobased COC transition is a 2026-to-2028 event that repositions the competitive landscape, or a slow-moving process that allows petroleum-based incumbents to maintain commodity pricing pressure for another market cycle. The bull case is stronger today because the regulatory direction is unambiguous—disclosure requirements are expanding, not contracting—and because the agrochemical industry's own label co-specification trend is already pulling validated COC products into structured demand channels regardless of EPA timing.

Market at a Glance

Regional performance: Where crop oil concentrates are growing fastest

North America is the largest revenue contributor, accounting for an estimated 44% of global crop oil concentrate sales in 2024, anchored by the scale of herbicide-intensive corn, soybean, cotton, and wheat production across the U.S. Midwest and Southern Plains. The U.S. market is mature in volume terms but is undergoing a formulation transition toward methylated seed oils and biobased alternatives, which is elevating average selling prices and supporting above-GDP revenue growth. Canada contributes meaningfully through canola production, where COC adjuvants are embedded in herbicide application programs. Latin America, particularly Brazil and Argentina, represents the second most important revenue bloc, driven by the sheer scale of soybean and sugarcane cultivation and rising farmer awareness of adjuvant-driven yield preservation.

Asia-Pacific carries the highest regional growth rate at an estimated 7.8% CAGR through 2034, driven by India's herbicide adoption surge in rice and wheat cultivation, where labor cost increases are forcing weed management mechanisation and chemical intensification. China's domestic agrochemical reformulation effort—part of its 14th Five-Year Plan agricultural efficiency mandate—is expanding adjuvant use in corn and vegetable production at the provincial level. Europe presents a mixed picture: Western Europe faces regulatory headwinds under the Farm to Fork Strategy, which is restricting petroleum-based adjuvants, but Eastern Europe, particularly Poland and Ukraine, is expanding COC use in cereal crops and sunflowers. The Middle East and Africa is a nascent but fast-growing market as commercial farming expands in Sub-Saharan Africa with development finance backing.

Leading Market Participants

• Wilbur-Ellis Company
• Helena Agri-Enterprises
• Winfield United
• Nufarm Limited
• Brandt Consolidated
• Loveland Products
• Interagro (UK) Ltd
• Precision Laboratories
• Drexel Chemical Company
• Adjuvants Plus Inc.

Where crop oil concentrates are headed by 2034

By 2034, the crop oil concentrates market will be structurally bifurcated between commodity petroleum-based formulations serving price-sensitive growers in developing markets and premium biobased or high-functionality adjuvant platforms commanding margin in North America, Europe, and developed Asia-Pacific. The commodity tier will face persistent price compression from generic manufacturers in China and India, while the premium tier will benefit from regulatory tailwinds and herbicide label co-specification. Market concentration will increase modestly at the distribution level, as regional co-ops and large agrochemical distributors continue to consolidate private-label adjuvant sourcing, reducing the number of viable branded COC suppliers from today's fragmented landscape to a smaller set of technically differentiated players.

Wilbur-Ellis and Brandt Consolidated are best positioned for 2034 because both companies have invested in proprietary biobased formulation platforms and maintain agronomist-level technical sales forces capable of defending premium pricing against private-label competition. Winfield United's integration within the Land O'Lakes cooperative network gives it structural distribution depth in the U.S. Corn Belt that independent adjuvant companies cannot replicate. Nufarm's global herbicide portfolio creates natural co-specification opportunities for its adjuvant lines in Australia and Latin America. The companies least likely to be relevant at market scale in 2034 are those whose competitive position rests solely on petroleum-based commodity formulations without a credible biobased transition strategy currently underway.

Market Segmentation

By Product Type

• Petroleum-Based Crop Oil Concentrates
• Vegetable Oil-Based Concentrates
• Methylated Seed Oil Adjuvants
• Blend Formulations
• High-Surfactant Crop Oils

By Crop Type

• Corn and Maize
• Soybeans
• Cotton
• Wheat and Cereals
• Fruits and Vegetables
• Rice

By Application

• Herbicide Enhancement
• Insecticide Enhancement
• Fungicide Enhancement
• Foliar Fertiliser Delivery
• Biological Pesticide Delivery

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Frequently Asked Questions

Q1. What is driving growth in the crop oil concentrates market beyond simple volume expansion in herbicide use? ▼

Herbicide resistance is forcing more complex tank mixes that require validated adjuvant support, increasing COC attachment rates per application event. Simultaneously, no-till agriculture expansion globally is structurally increasing post-emergent herbicide dependence, where COC use is highest.

Q2. Is the biobased COC transition a genuine market shift or a regulatory compliance exercise with limited commercial impact? ▼

It is a genuine commercial shift. EPA labelling reform and herbicide label co-specification by manufacturers like BASF and Corteva are creating structured demand for technically validated biobased COC products that commodity petroleum formulations cannot satisfy.

Q3. Which region offers the best near-term entry opportunity for a new crop oil concentrate supplier? ▼

Asia-Pacific, specifically India and Vietnam, offers the best near-term entry point because herbicide adoption is accelerating rapidly and the adjuvant market remains underpenetrated relative to herbicide volume. Local regulatory requirements are less restrictive than in North America or the EU.

Q4. How exposed is this market to a sustained downturn in global commodity crop prices? ▼

Meaningfully exposed in the short term, as documented by the 6 to 9% adjuvant volume decline in the U.S. Corn Belt during the 2023 soft commodity price cycle. However, the herbicide resistance structural driver limits the duration of demand suppression because growers cannot abandon weed management.

Q5. Which competitive dynamic poses the greatest threat to branded COC manufacturers over the forecast period? ▼

Private-label penetration through co-ops and large distributors, which already exceeds 38% of U.S. volume, is the primary threat. Branded manufacturers must demonstrate technical differentiation through biological compatibility, tank-mix stability data, or label co-specification to defend margin against generic displacement.